HC Wainwright Has Bearish Estimate for RNAC Q2 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of Cartesian Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.68) for the quarter, down from their prior forecast of ($0.67). HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics' FY2025 earnings at ($2.80) EPS.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The company had revenue of $1.10 million for the quarter, compared to analysts' expectations of $0.69 million.

Separately, Needham & Company LLC lowered their price objective on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.50.

Cartesian Therapeutics Trading Up 0.1%

Shares of NASDAQ RNAC traded up $0.01 during mid-day trading on Wednesday, reaching $9.16. The company had a trading volume of 53,651 shares, compared to its average volume of 114,983. The firm has a 50 day simple moving average of $11.69 and a two-hundred day simple moving average of $16.34. The stock has a market cap of $237.74 million, a P/E ratio of -0.17 and a beta of 0.51. Cartesian Therapeutics has a 52-week low of $8.85 and a 52-week high of $41.87.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RNAC. Barclays PLC grew its position in Cartesian Therapeutics by 208.6% during the 3rd quarter. Barclays PLC now owns 11,611 shares of the company's stock worth $188,000 after purchasing an additional 7,849 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Cartesian Therapeutics in the 4th quarter worth $97,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Cartesian Therapeutics by 22.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company's stock worth $82,000 after acquiring an additional 847 shares during the period. Rhumbline Advisers lifted its stake in shares of Cartesian Therapeutics by 10.0% in the 4th quarter. Rhumbline Advisers now owns 10,201 shares of the company's stock worth $183,000 after acquiring an additional 927 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Cartesian Therapeutics by 28.5% in the 4th quarter. Bank of New York Mellon Corp now owns 19,407 shares of the company's stock worth $348,000 after acquiring an additional 4,305 shares during the period. 86.95% of the stock is owned by hedge funds and other institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.